Biomedical Engineering Reference
In-Depth Information
Biochemical parameters of
human serum / Unit
Normal
values
Control
AAm
AAm/CA AAm/MA AAm/IA
Glucose/mg dl
-1
70-110
87.0±8.2
91.0± 6.1
88.1±3.99
88.8±6.0
88.4±5.30
Triglyceride/mg dl
-1
40-160
127.3±24.6 127.0±25.8 130.6±19.9 127.2±25.1
125.6±20.7
Cholesterol/mg dl
-1
125-350 158.6±10.9 160.6±14.3 159.8±11.3 157.8±10.8
160.6±14.3
BUN/mg dl
-1
8-25
14.8±1.27
15.2±4.56
14.6±3.73
15.2±4.10
15.6±3.84
Creatinin/mg dl
-1
0.8-1.6
0.98±0.14
1.06±0.17
1.02±0.14
0.98±0.18
1.00±0.18
Total protein/g dl
-1
6.0-8.4
6.52±0.15
6.72±0.15
6.70±0.13
6.60±0.22
6.48±0.30
Albumin/mg dl
-1
3.5-5.6
4.02±0.15
3.88±0.15
3.98±0.18
3.96±0.20
3.94±0.10
Alkaline phosphatase/U
35-125
53.6± 13.1
54.5±12.3
54.0±14.9
52.6±12.6
52.6± 10.3
Alanine transaminase/U
7-56
14.6±2.12
16.0±2.63
15.7±3.23
15.9±2.47 16.0±2.63
Aspartate transaminase/U
5-40
16.2±5.33
15.2±3.19
16.5±3.03
17.2±5.16
15.2±3.19
Direct bilirubin/mg dl
-1
0.0-0.3
0.12±0.04
0.12±0.04
0.11±0.03
0.11±0.03
0.12±0.04
Indirect bilirubin/mg dl
-1
0.1-1.1
0.45±0.05
0.35±0.09
0.35±0.09
0.45±0.05
0.40±0.07
Chlorine/meq dl
-1
95-107
98.5±2.17
98.8±2.3 98.6±2.12
97.8±1.75
98.2±2.10
Sodium/meq dl
-1
137-146
142.7±1.4
142.8± 0.9
143.0±1.6
142.7±1.4
142.0±1.6
Potassium/meq dl
-1
3.5-5.5
4.80±0.28
4.68±0.36
4.94±0.39
4.87±0.35
4.70±0.35
Calcium/mg dl
-1
8.5-10.8
9.40±0.39
9.47±0.28
9.42±0.28
9.63±0.42
9.47±0.28
Phosphorus/mg dl
-1
2.5-4.5
3.60±0.41
3.60±0.32
3.68±0.42
3.60±0.36
3.56±0.38
Table 3. Means and standard deviations of biochemical parameters of human sera
these fibrous capsules consisting of fibroblasts, and a grouped mast cells and lymphocyte
were observed between tissues and capsule in the some samples (Figure 15, 16).
Fig. 15. After one week, the implan-tation site of AAm hydrogel, H-E, 20X
After 6-10 weeks, the adverse tissue reaction, giant cells and necrosis of cells, inflammatory
reaction such as deposition of foamed macrophage were not observed in the implant site,
however, it is observed to increase in the collagen fibrils due to proliferation and activation
of fibroblasts (Fig. 17). No chronic and acute inflammation, adverse tissue reaction were
observed in the all test groups. It is no determination related to the loss of activation and
liveliness of cells in the capsule cells and in distant sites. No pathology were observed in the
skin and the tissues of straight muscle in the close to implant sites.
